Australia's most trusted
source of pharma news
Posted 7 November 2024 AM
AstraZeneca lost $25.9 billion in market value on Monday in a fall attributed to an ongoing Chinese investigation into the company coupled with disappointing results for its obesity candidate.
The woes started in early September with reports Chinese police had detained five current and former AstraZeneca employees in relation to an investigation into possible breaches relating to data privacy and importing unlicensed medications, with that number now understood to be eight or nine.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.